La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2016 Global Healthcare Conference
June 06 2016 - 8:00AM
Business Wire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or
La Jolla), a leader in the development of innovative therapies
intended to significantly improve outcomes in patients suffering
from life-threatening diseases, today announced that George F.
Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La
Jolla, will provide a corporate overview at the Jefferies 2016
Global Healthcare Conference taking place June 7–10 in New York
City.
Jefferies 2016 Global Healthcare
Conference Presentation Details
Date: Tuesday, June 7, 2016 Time: 9:00 a.m. Eastern
Time Location: Ballroom 5 @ Grand Hyatt Hotel New York Webcast:
LJPC Webcast Link
A live webcast of the presentation will also be available in the
Investor Relations section of La Jolla’s website at www.ljpc.com. A
replay of the presentation will be available on La Jolla’s website
for 30 days following the event.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company
focused on the discovery, development and commercialization of
innovative therapies intended to significantly improve outcomes in
patients suffering from life-threatening diseases. The Company has
several product candidates in development. LJPC-501 is La Jolla’s
proprietary formulation of angiotensin II for the potential
treatment of catecholamine-resistant hypotension. LJPC-401 is La
Jolla’s novel formulation of hepcidin for the potential treatment
of conditions characterized by iron overload, such as hereditary
hemochromatosis, beta thalassemia, sickle cell disease and
myelodysplastic syndrome. LJPC-30S is our next-generation
gentamicin derivative program that is focused on therapeutics for
the potential treatment of serious bacterial infections as well as
rare genetic disorders, such as cystic fibrosis and Duchenne
muscular dystrophy. For more information on La Jolla, please visit
www.ljpc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160606005584/en/
La Jolla Pharmaceutical CompanySandra Vedrick,
858-256-7910Senior Manager Investor Relations & Human
Resourcessvedrick@ljpc.comorDennis M. Mulroy, 858-433-6839Chief
Financial Officerdmulroy@ljpc.com
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Apr 2023 to Apr 2024
